港股创新药板块持续走高，港股创新药ETF(159567)跟踪指数领跑港股市场，再鼎医药、金斯瑞生物科技、荣昌生物领涨。

有连云06-04

2024年6月4日，港股创新药板块大幅上涨。盘面上，再鼎医药领涨，金斯瑞生物科技、荣昌生物跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到7088万元。中信建投表示，美国临床肿瘤学会（ASCO）年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，汇集了众多世界一流的肿瘤学专家一起分享探讨当前最前沿的临床肿瘤学科研成果和治疗技术，同时很多重要的研究发现和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2440547671?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-04 13:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2440547671","market":"sh","top_or_hot":-1,"title":"港股创新药板块持续走高，港股创新药ETF(159567)跟踪指数领跑港股市场，再鼎医药、金斯瑞生物科技、荣昌生物领涨。","media":"有连云","content":"<div>\n<p>2024年6月4日，港股创新药板块大幅上涨。盘面上，再鼎医药领涨，金斯瑞生物科技、荣昌生物跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到7088万元。中信建投表示，美国临床肿瘤学会（ASCO）年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，汇集了众多世界一流的肿瘤学专家一起分享探讨当前最前沿的临床肿瘤学科研成果和治疗技术，同时很多重要的研究发现和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041331539f179dec&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股创新药板块持续走高，港股创新药ETF(159567)跟踪指数领跑港股市场，再鼎医药、金斯瑞生物科技、荣昌生物领涨。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股创新药板块持续走高，港股创新药ETF(159567)跟踪指数领跑港股市场，再鼎医药、金斯瑞生物科技、荣昌生物领涨。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-04 13:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041331539f179dec&s=b><strong>有连云</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024年6月4日，港股创新药板块大幅上涨。盘面上，再鼎医药领涨，金斯瑞生物科技、荣昌生物跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到7088万元。中信建投表示，美国临床肿瘤学会（ASCO）年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，汇集了众多世界一流的肿瘤学专家一起分享探讨当前最前沿的临床肿瘤学科研成果和治疗技术，同时很多重要的研究发现和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041331539f179dec&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"513120","symbol_name":"港股创新药ETF","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041331539f179dec&s=b","article_id":"2440547671","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041331539f179dec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2440547671","pubTimestamp":1717479106,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2024年6月4日，港股创新药板块大幅上涨。盘面上，再鼎医药领涨，金斯瑞生物科技、荣昌生物跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额达到7088万元。在此前公布的摘要中，有21项中国研究入选口头报告，27项中国研究入选快速口头报告，7项中国研究入选临床科学研讨会，国内企业持续发力，创新度持续提升，持续看好创新药产业技术驱动周期，建议持续关注ADC及新型疗法。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159567":"HK创新药","159992":"创新药","513120":"港股创新药ETF","688331":"荣昌生物","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","09995":"荣昌生物"},"translate_title":"The innovative drug sector of the Hong Kong stock market continued to rise. The Hong Kong stock innovative drug ETF (159567) tracking index led the Hong Kong stock market, and Zai Lab, GenScript Biotechnology, and Rongchang Biotech led the gains.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159567":1,"159992":1,"513120":1,"688331":1,"09995":0.9},"content_text":"2024年6月4日，港股创新药板块大幅上涨。盘面上，再鼎医药领涨，金斯瑞生物科技、荣昌生物跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到7088万元。中信建投表示，美国临床肿瘤学会（ASCO）年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，汇集了众多世界一流的肿瘤学专家一起分享探讨当前最前沿的临床肿瘤学科研成果和治疗技术，同时很多重要的研究发现和临床试验成果也会选择在ASCO年会上进行首次发布。在此前公布的摘要中，有21项中国研究入选口头报告，27项中国研究入选快速口头报告，7项中国研究入选临床科学研讨会，国内企业持续发力，创新度持续提升，持续看好创新药产业技术驱动周期，建议持续关注ADC及新型疗法。相关产品：港股创新药ETF（159567）本条资讯内容与数据仅供参考，不构成投资建议。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440547671"}